Sierra Leone’s President Julius Maada Bio Chairs Session to Build Momentum for Routine Immunisation Recovery in Africa on the Side Event of African Union (AU) Assembly
ADDIS ABABA, Ethiopia, February 20, 2023/APO Group/ —
His Excellency President Dr Julius Maada Bio has chaired the side event of the African Union, AU, to discuss reducing vaccine-preventable deaths and illnesses and to galvanise momentum towards achieving universal immunisation.
He started by highlighting his country’s specific investment in vaccines and immunisation, adding that Sierra Leone remained committed to achieving the Immunisation Agenda 2030 as well as the African Regional Strategic Plan on immunisation.
“We believe that it is possible to achieve the national and global immunisation targets, including eradication and elimination goals. Progress in meeting immunisation targets, we believe, is a driver for equitable health outcomes for children, mothers, and the population as a whole.
“My government’s immunisation programme is embedded within the country’s primary health care system. The period 2021 and 2022 saw the consolidation of the gains in the immunisation system. This period saw a stable and high immunisation coverage for key antigens; 93% and 94% for measles and 96% and 94% for DPT3 for the period 2021 and 2022 respectively,” he averred.
President Julius Maada Bio also recalled that the country’s Ministry of Health and Sanitation had introduced new vaccines that included the rota-virus vaccine in 2016, the pneumococcal vaccine in 2018, changed from the measles to the Measles-Rubella Vaccine in 2019 and as part of the polio eradication initiative introduced 2 doses of Inactivated Polio Vaccine into the routine immunisation programme.
“As part of the ambitious national cervical cancer elimination strategy, in October 2022 we introduced the Human Papilloma Virus (HPV) vaccine as a strategy to eliminate Cervical Cancer by 2030. Over a 2-week period, 183,218 girls aged 10 years were vaccinated nationwide using a combination of school-based and community outreach strategies.
The period 2021 and 2022 saw a stable and high immunisation coverage for key antigens; 93% and 94% for measles and 96% and 94% for DPT3
“In Sierra Leone, 20% of under-five mortality is due to malaria. The new malaria vaccine, planned for introduction in 2024 will reduce hospitalisation for severe malaria and all-cause mortality in under-5 children.
“As part of our commitment to the Immunisation Agenda 2030 and the African Regional Strategic Plan on Immunisation, we have paid all the co-financing requirements for vaccine supplies including an advance payment for 2023 despite the economic challenges that my country faces.
“We have committed $ 806,238 for 575,370 doses of routine vaccines (DPT, PCV, MR, Rota, Yellow fever, HPV) and allocated funds for 1 million doses of the new malaria vaccine in the 2023 budget. In line with the Gavi 5.0 strategy that emphasises country ownership, government has also committed funds in the 2023 budget to start paying for traditional vaccines (BCG, oral Polio, Tetanus-Diphtheria for pregnant women),” he said.
The President, who was accompanied to the event by his Minister of Health and Sanitation, Dr Austin Demby, told the gathering that they believed, as a government, that the returns on investment for immunisation were very high for the country’s progress towards meeting the SDGs. He added that that was reflected in his government’s national immunisation policies, its integrated service delivery programme, and its commitment to working with multiple stakeholders in order to expand coverage.
He closed by talking about the country’s recent success dealing with the COVID-19 outbreak in Sierra Leone, noting that the pandemic had a negative impact on the country’s immunisation performance.
“COVID-19 public emergency restrictions, initial concerns about the safety of healthcare facilities, rumours and misinformation about vaccine safety, all prevented or limited access to immunisation services. Between March and May of 2020, there was a significant reduction in routine immunisation coverage. DPT3 dropped from 92% coverage in January 2020 to 74% in April of the same year.
“However, due to the robust COVID-19 outbreak response, and our strong routine immunisation systems as well as the well-established primary health care structures, the drop in immunisation coverage only lasted for a few months. By June of 2020, immunisation coverage had recovered to pre-COVID-19 levels. The immunisation coverage for other immunisation antigens also followed a similar pattern.
“By January 2023, over 73% of the eligible population had been fully vaccinated for COVID-19. We are now incorporating COVID-19 vaccination into our routine immunisation program. We are capitalising on resources from the COVID-19 vaccination support from partners and additional Government resources to strengthen our routine immunisation systems,” he closed